83683-90-3

Usage

Uses

Used in Pharmaceutical Industry:
(2R,3R,4R,5R)-2-(5-amino-2,9-diazabicyclo[4.3.0]nona-1,3,5,7-tetraen-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol is used as a potential therapeutic agent for various medical conditions due to its unique structure and biological activity.
Used in Scientific Research:
(2R,3R,4R,5R)-2-(5-amino-2,9-diazabicyclo[4.3.0]nona-1,3,5,7-tetraen-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol is used as a research compound for studying its properties and potential applications in various scientific fields.
Further analysis and experimentation are necessary to fully understand the properties and potential uses of this complex molecule.

InChI:InChI=1/C12H15N3O4/c13-7-1-3-14-11-6(7)2-4-15(11)12-10(18)9(17)8(5-16)19-12/h1-4,8-10,12,16-18H,5H2,(H2,13,14)/t8-,9-,10-,12-/m1/s1

Upstream product

• 83683-88-9 4-(acetylamino)-1-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-2,3-dihydro-1H-pyrrolo<2,3-b>pyridine 
• 13035-61-5 1,2,3,5-tetraacetylribose 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 83683-85-6 1-acetyl-4-(acetylamino)-2,3-dihydro-1H-pyrrolo<2,3-b>pyridine 
• 83683-87-8 4-(acetylamino)-2,3-dihydro-1H-pyrrolo<2,3-b>pyridine 
• 83683-83-4 4-amino-2,3-dihydro-1H-pyrrolo<2,3-b>pyridine 
• 83683-82-3 4-nitro-1H-pyrrolo<2,3-b>pyridine 
• 74420-06-7 4-nitro-1H-pyrrolo<2,3-b>pyridine 7-oxide 
• 271-63-6 7-Azaindole 
• 83683-89-0 4-(acetylamino)-1-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-1H-pyrrolo<2,3-b>pyridine 

Relevant academic research and scientific papers

Discovery of Pyrrolo[2,3- b]pyridine (1,7-Dideazapurine) Nucleoside Analogues as Anti- Trypanosoma cruzi Agents

Trypanosoma cruzi is the causative pathogen of Chagas disease and the main culprit for cardiac-related mortality in Latin-America triggered by an infective agent. Incapable of synthesizing purines de novo, this parasite depends on acquisition and processing of host-derived purines, making purine (nucleoside) analogues a potential source of antitrypanosomal agents. In this respect, hitherto 7-deazaadenosine (tubercidin) analogues attracted most attention. Here, we investigated analogues with an additional nitrogen (N1) removed. Structure-activity relationship investigation showed that C7 modification afforded analogues with potent antitrypanosomal activity. Halogens and small, linear carbon-based substituents were preferred. Compound 11 proved most potent in vitro, showed full suppression of parasitemia in a mouse model of acute infection, and elicited 100% animal survival after oral dosing at 25 mg/kg b.i.d. for 5 and 15 days. Cyclophosphamide-induced immunosuppression led to recrudescence. Washout experiments demonstrated a lack of complete clearance of infected cell cultures, potentially explaining the in vivo results.